| Patent Number |
Title Of Patent |
Date Issued |
| 7402308 |
Method of delivering genes to the central nervous system of a mammal |
July 22, 2008 |
| The invention provides a method of delivering a selected DNA sequence to the central nervous system of a mammal by administering to said mammal a neurotropic virus, said virus containing a selected DNA sequence under the control of a promoter which permits expression of the DNA during th |
| 7354589 |
Multiple antigenic agents and methods for using the same |
April 8, 2008 |
| The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections. The multiple antigenic agents of the invention contain at least one of a B cell determinant, a T cell determinant, or a targeting molecule attached to a cor |
| 7189801 |
Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function |
March 13, 2007 |
| The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360 386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and of select tumor |
| 7122633 |
Natural killer stimulatory factor |
October 17, 2006 |
| This application relates to antibodies reactive with a novel homogenous human cytokine, Natural Killer Stimulator Factor (NKSF), having the ability to induce the production of gamma interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing |
| 7001759 |
Compositions and methods for delivery of genetic material |
February 21, 2006 |
| Methods of introducing genetic material into cells of an individual and compositions and kits for practicing the same are disclosed. The methods comprise the steps of contacting cells of an individual with a polynucleotide function enhancer and administering to the cells, a nucleic a |
| 6852706 |
Methods and compositions for healing heart wounds |
February 8, 2005 |
| Levels of thyroid hormone can be decreased in a mammal to increase healing of heart wounds. The increased wound healing includes rapid re-epithelialization and recovery of normal architecture and function relative to mammals who have not been treated according to the invention. |
| 6838236 |
VPR function and activity |
January 4, 2005 |
| Pharmaceutical compositions comprising the HIV protein vpr or nucleic acid molecule encoding vpr are disclosed. Also disclosed are methods of treating patients suffering from diseases characterized by hyperproliferating undifferentiated cells such as cancer by administering such comp |
| 6638408 |
Method and device for separation of charged molecules by solution isoelectric focusing |
October 28, 2003 |
| The invention provides a novel solution isoelectric focusing device and method that can reproducibly fractionate charged molecules into well-defined pools. This approach can be applied to mixtures of charged molecules, such as eukaryotic proteome samples where reproducible resolution |
| 6555658 |
Antibodies to natural killer stimulatory factor |
April 29, 2003 |
| This application relates to antibodies reactive with a novel homogenous human cytokine, Natural Killer Stimulator Factor (NKSF), having the ability to induce the production of gamma interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing |
| 6555579 |
Methods for reducing atherosclerotic plaques |
April 29, 2003 |
| A method for reducing atherosclerotic plaques includes administering an effective amount of at least one fatty acid composition to an animal, said fatty acid composition having a carbon chain of at least 16 carbons in length, and wherein at least one pair of double bonds are in a conjuga |
| 6538173 |
Compositions and methods for wound healing |
March 25, 2003 |
| Mice in which enhance wound healing occurs can be used to identify genes and gene products which are involved in enhanced wound healing in mammals, including humans. Methods and compositions for treating wounds, including central and peripheral nerve wounds, are also provided. |
| 6468982 |
Genetic immunization |
October 22, 2002 |
| Methods of prophylactic and therapeutic immunization of an individual against pathogen infection, diseases associated with hyperproliferative cells and autoimmune diseases are disclosed. The methods comprise the steps of administering to cells of an individual, a nucleic acid molecule |
| 6420118 |
Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function |
July 16, 2002 |
| The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360-386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and of select tumor |
| 6245886 |
Peptides and peptidomimetics with structural similarity to human P53 that activate P53 function |
June 12, 2001 |
| The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360-386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and to select tumor |
| 6221635 |
Methods for solid-phase amplification of DNA template (SPADT) using multiarrays |
April 24, 2001 |
| The present invention relates to a novel method of detecting specific nucleic acids in a biological sample using solid-phase amplification of DNA template (SPADT) using multiarrays. |
| 6169073 |
Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function |
January 2, 2001 |
| The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360-386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and of select tumor |
| 5981505 |
Compositions and methods for delivery of genetic material |
November 9, 1999 |
| Methods of inducing genetic material into cells of an individual and compositions and kits for practicing the same are disclosed. The methods comprise the steps of contacting cells of an individual with a polynucleotide function enhancer and administering to the cells, a nucleic acid |
| 5874225 |
Identification of compounds that modulate HIV-1 vpr protein activity |
February 23, 1999 |
| The present invention is directed toward methods of identifying compounds which inhibit the human immunodeficiency virus (HIV) viral protein R (Vpr) from stimulating the differentiation of undifferentiated cells. This invention takes advantage of the observation that cell lines from |
| 5837460 |
Methods of identifying biologically active receptor-binding peptides |
November 17, 1998 |
| A method of identifying peptides which mimic biologically active proteins is disclosed. The method comprises the steps of making a recombinant antibody library from genetic material obtained from an animal which has been immunized against antibodies that bind to the biological active |
| 5837249 |
Method for generating an immunogenic T cell response protective against a virus |
November 17, 1998 |
| A novel method of presenting an immunogenic peptide to an antigen presenting cell (APC) of a mammalian host, in order to generate a T cell response protective against a virus, such as herpes or rabies virus, comprising administering an immunologically effective amount of (1) a peptid |
| 5830876 |
Genetic immunization |
November 3, 1998 |
| A method of immunizing an individual against pathogen is disclosed. Also disclosed is a method of treating an individual who has a hyperproliferative disease, or of treating an individual who is infected by a pathogen. Specifically, the individual is injected with bupivacaine along w |
| 5817637 |
Genetic immunization |
October 6, 1998 |
| Methods of prophylactic and therapeutic immunization of an individual against pathogen infection, diseases associated with hyperproliferative cells and autoimmune diseases are disclosed. The methods comprise the steps of administering to cells of an individual, a nucleic acid molecule |
| 5668002 |
DNA and polypeptide for tumor-associated antigen CO-029 |
September 16, 1997 |
| The human tumor-associated antigen CO-029 is a monoclonal antibody-defined, 27-34 kDa cell surface glycoprotein. A full-length cDNA clone for CO-029 is described. When transiently expressed in COS cells, the cDNA clone directs the synthesis of an antigen reactive with monoclonal antibody |
| 5637677 |
Biologically active compounds and methods of constructing and using the same |
June 10, 1997 |
| A method of constructing biologically active compounds which mimic the biological activity of the biologically active protein or which block the activity of the biologically active protein is disclosed. A method of identifying specific and discrete portions of pathogen antigens which |
| 5595869 |
Diagnostic methods for detecting lymphomas in humans |
January 21, 1997 |
| The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. This translocation |
| 5593972 |
Genetic immunization |
January 14, 1997 |
| Methods of prophylactic and therapeutic immunization of an individual against pathogen infection, diseases associated with hyperproliferative cells and autoimmune diseases are disclosed. The methods comprise the steps of administering to cells of an individual, a nucleic acid molecule |
| 5523393 |
BCL-2 proteins |
June 4, 1996 |
| The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. This translocation |
| 5506344 |
Antibodies specific for BCL-2 gene product |
April 9, 1996 |
| The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. This translocation |
| 5470571 |
Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specifi |
November 28, 1995 |
| Monoclonal antibody 425 having properties particularly beneficial for anti-tumor therapy has been raised. MAb 425 antibody binds to EGF-receptors and inhibits their bioactivities. The amount of binding of the antibody to cancer cells can be increased by treatment of the cells with ly |
| 5459251 |
DNA molecules having human bcl-2 gene sequences |
October 17, 1995 |
| The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. This translocation |
| 5225535 |
Lymphokine SAF and method of making |
July 6, 1993 |
| A lymphokine is taught which can be used to activate and stimulate CD3.sup.+, CD4.sup.+ T cells, as well as Sezary leukemic T cells. The lymphokine can be obtained from mitogen-stimulated peripheral blood mononuclear cells or urine of Sezary Syndrome patients. The lymphokine upregula |
| 5202429 |
DNA molecules having human BCL-2 gene sequences |
April 13, 1993 |
| The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. The translocation |
| 5185254 |
Gene family of tumor-associated antigens |
February 9, 1993 |
| A tumor-associated antigen, GA733-1, has been discovered which shares sequence homology with both thyroglobulin type I and interleukin-2 receptors. The antigen is highly expressed in pancreatic carcinoma cells. The antigen is similar to a previously described tumor-associated antigen |
| 5182192 |
Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and us |
January 26, 1993 |
| The present invention is directed to in vitro and in vivo immunodiagnosis and immunotherapy using monoclonal antibodies reactive with difucosyl blood group antigens Y-6 and B-7-2. |
| 5169775 |
Monoclonal antibodies against lymphoma-associated antigens, hybrid cell lines producing these an |
December 8, 1992 |
| The present invention is directed to monoclonal antibodies, and hybridomas which produce them, which are preferentially reactive with canine lymphoma cells and insignificantly reactive with normal canine lymphocytes. |
| 5130127 |
Human tumor therapy using beta (1-3) glucanlentinan and anti-tumor antibodies |
July 14, 1992 |
| A therapeutic method for treating human tumors in vivo is provided wherein lentinan is administered to the patient followed by treatment with anti-tumor monoclonal antibodies. |
| 5015568 |
Diagnostic methods for detecting lymphomas in humans |
May 14, 1991 |
| The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. This translocation |
| 4994387 |
Process and medium for cloning and long-term serial cultivation of human endothelial cells |
February 19, 1991 |
| Vigorous growth of endothelial cells from human umbilical vein endothelial cells in vitro is achieved using a culture medium containing endothelial cell growth factor and heparin and/or dextran sulfate. Cell population doubling times of 13 to 21 hours for 60 to 85 populations doublings a |
| 4971792 |
Monoclonal antibodies against glycolipid antigens |
November 20, 1990 |
| The present invention is directed to in vitro and in vivo immunodiagnosis and immunotherapy using monoclonal antibodies reactive with difucosyl blood group antigens Y-6 and B-7-2. |
| 4849509 |
Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these |
July 18, 1989 |
| The present invention is directed to monoclonal antibodies, and hybridomas which produce them, which are reactive with ganglioside antigens GD2 and GD3 and are essentially non-reactive with other ganglioside antigens. The invention further relates to methods of using these antibodies. |
| 4830726 |
Separation of large DNA molecules in alternating asymmetric electric fields |
May 16, 1989 |
| A method of separating DNA molecules by gel electrophoresis is disclosed which employs alternate application of high and low strength electric fields in opposite directions to a gel matrix containing DNA. The high strength field is maintained for a shorter interval than the low strength |
| 4731237 |
Immune response to virus induced by anti-idiotype antibodies |
March 15, 1988 |
| A method of inducing an immunological response in a host to a virus is provided employing anti-idiotype antibodies that present an internal image of a viral antigen to the host. Anti-idiotype antibodies and the cell lines that produce such antibodies are also provided. |
| 4701409 |
Detection of B-cell neoplasms |
October 20, 1987 |
| B-cell neoplasm is detected by hybridizing lymphocytic DNA with DNA probes that identify chromosomal translocations between human chromosomes 11 and 18. |
| 4693975 |
Human hybridroma fusion partner for production of human monoclonal antibodies |
September 15, 1987 |
| Somatic cell hybrids of purely human origin are described that are suitable fusion partners for producing hybridomas by fusion with antibody producing cells, which hybridomas are stable and continuous. |
| 4608337 |
Human hybridomas and the production of human monoclonal antibodies by human hybridomas |
August 26, 1986 |
| The present invention provides a stable, continuous human myeloma cell line which is capable of hybridization with antibody-producing cells of humans and other animals, the cell line being a mutant of GM 1500 human B cells and being deficient in hypoxanthine phosphoribosyltransferase. Th |
| 4607009 |
Lewis blood group phenotype assay |
August 19, 1986 |
| An assay for determining the Lewis blood group of a patient consists of testing a body sample for the presence of Lewis.sup.a and Lewis.sup.b antigens. Monoclonal antibodies specific for either of these antigens are employed which do not cross-react with other related antigens, such as t |
| 4471057 |
Detection of colorectal carcinoma |
September 11, 1984 |
| Colorectal carcinoma is detected by testing body fluids for the colorectal carcinoma monosialoganglioside identified by monoclonal antibodies produced by fused cell hybrid ATCC HB 8059. |
| 4393201 |
DNA Which codes for glycoprotein of era-strain rabies virus |
July 12, 1983 |
| The present invention provides a cDNA which carries the code for the glycoprotein of the ERA-strain rabies virus. |
| 4349528 |
Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen |
September 14, 1982 |
| It has been determined that 180,000 dalton molecular weight carcinoembryonic antigen has an antigen site which is not shared by other molecular weight carcinoembryonic antigens, which are released by colorectal carcinoma. A hybridoma antibody specific for the 180,000 dalton molecular |
| 4196265 |
Method of producing antibodies |
April 1, 1980 |
| Continuous cell lines of genetically stable fused cell hybrids capable of producing large amounts of monoclonal antibodies against specific viruses and their antigenic determinants have been developed. The cell lines are fused cell hybrids between viral antibody producing cells and myelo |
